[go: up one dir, main page]

WO2001074341A3 - Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux - Google Patents

Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux Download PDF

Info

Publication number
WO2001074341A3
WO2001074341A3 PCT/US2001/010019 US0110019W WO0174341A3 WO 2001074341 A3 WO2001074341 A3 WO 2001074341A3 US 0110019 W US0110019 W US 0110019W WO 0174341 A3 WO0174341 A3 WO 0174341A3
Authority
WO
WIPO (PCT)
Prior art keywords
expectorant
inflammatory conditions
cough
composition
treating allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010019
Other languages
English (en)
Other versions
WO2001074341A2 (fr
Inventor
Lugo Sergio Rolando Ulloa
Ramos Jose De Jesus Villacampa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to NZ520826A priority Critical patent/NZ520826A/en
Priority to AU4786701A priority patent/AU4786701A/xx
Priority to AU2001247867A priority patent/AU2001247867B2/en
Publication of WO2001074341A2 publication Critical patent/WO2001074341A2/fr
Publication of WO2001074341A3 publication Critical patent/WO2001074341A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'un antihistaminique non sédatif en combinaison avec un expectorant pour la préparation d'un médicament adapté au traitement et/ou à la prévention d'états allergiques et inflammatoires avec toux chez des patients nécessitant un tel traitement et/ou une telle prévention. On utilise une quantité efficace de l'antihistaminique cité, de préférence de la loratadine, en combinaison avec un expectorant, de préférence de l'ambroxol. L'invention concerne également des compositions pharmaceutiques pour le traitement et/ou la prévention des états considérés chez, dans lesquelles on trouve une quantité efficace de cet antihistaminique en combinaison avec un expectorant et un vecteur pharmaceutiquement acceptable.
PCT/US2001/010019 2000-03-30 2001-03-28 Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux Ceased WO2001074341A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ520826A NZ520826A (en) 2000-03-30 2001-03-28 Compositions and methods for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
AU4786701A AU4786701A (en) 2000-03-30 2001-03-28 Compositions and methods for treating allergic and inflammatory conditions with cough
AU2001247867A AU2001247867B2 (en) 2000-03-30 2001-03-28 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19331000P 2000-03-30 2000-03-30
US60/193,310 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001074341A2 WO2001074341A2 (fr) 2001-10-11
WO2001074341A3 true WO2001074341A3 (fr) 2002-05-16

Family

ID=22713096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010019 Ceased WO2001074341A2 (fr) 2000-03-30 2001-03-28 Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux

Country Status (13)

Country Link
CN (1) CN1422162A (fr)
AR (1) AR025308A1 (fr)
AU (2) AU2001247867B2 (fr)
BR (1) BR0003648A (fr)
CO (1) CO5200779A1 (fr)
CR (1) CR6232A (fr)
NZ (1) NZ520826A (fr)
PA (1) PA8500101A1 (fr)
PE (1) PE20010576A1 (fr)
SG (1) SG96611A1 (fr)
TW (1) TWI243671B (fr)
WO (1) WO2001074341A2 (fr)
ZA (1) ZA200102605B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323662C (zh) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用
WO2005123052A1 (fr) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Composition medicamenteuse contenant de l'ambroxol et de l'erdosteine ou de l'acetylcysteine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004589A1 (fr) * 1984-04-09 1985-10-24 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments anti-inflammatoires non steraniques
WO1988008302A1 (fr) * 1987-04-24 1988-11-03 Abraham Sunshine Melanges contre la toux/le rhume comprenant des remedes d'antihistamine non sedative
WO1988009656A1 (fr) * 1987-06-08 1988-12-15 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments a base d'antihistaminiques sans effets sedatifs
WO1995007103A1 (fr) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions contenant un sel d'acide amine d'un agent anti-inflammatoire non steroidien a base d'acide propionique et au moins un decongestionnant ou un expectorant ou un antihistaminique ou un antitussif
WO1999066919A1 (fr) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004589A1 (fr) * 1984-04-09 1985-10-24 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments anti-inflammatoires non steraniques
WO1988008302A1 (fr) * 1987-04-24 1988-11-03 Abraham Sunshine Melanges contre la toux/le rhume comprenant des remedes d'antihistamine non sedative
WO1988009656A1 (fr) * 1987-06-08 1988-12-15 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments a base d'antihistaminiques sans effets sedatifs
WO1995007103A1 (fr) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions contenant un sel d'acide amine d'un agent anti-inflammatoire non steroidien a base d'acide propionique et au moins un decongestionnant ou un expectorant ou un antihistaminique ou un antitussif
WO1999066919A1 (fr) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif

Also Published As

Publication number Publication date
AU4786701A (en) 2001-10-15
ZA200102605B (en) 2001-10-03
PA8500101A1 (es) 2002-09-17
AU2001247867B2 (en) 2005-09-01
PE20010576A1 (es) 2001-05-08
CO5200779A1 (es) 2002-09-27
SG96611A1 (en) 2003-06-16
BR0003648A (pt) 2002-01-02
TWI243671B (en) 2005-11-21
WO2001074341A2 (fr) 2001-10-11
NZ520826A (en) 2004-07-30
CN1422162A (zh) 2003-06-04
CR6232A (es) 2008-12-01
AR025308A1 (es) 2002-11-20

Similar Documents

Publication Publication Date Title
WO2001087306A8 (fr) Compositions et methodes de traitement du cancer colorectal
WO2002085857A3 (fr) Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
MXPA01012184A (es) Composicion dietetica o farmaceutica para utilizarse en la prevencion o tratamiento de la hiperoxaluria.
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
WO2002056912A3 (fr) Methode de traitement du cancer
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
EP1600168A3 (fr) Dérivé de pyrrolidine acetamide, seul ou en combinaison, pour le traitement des maladies du système nerveux central
CA2363990A1 (fr) Utilisation de glycyrrhizine pour traiter une mastite
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2001062235A3 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
EP2138175A3 (fr) Formulations comprenant du valsartan pour traiter le diabète ou la microalbuminurie
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2003015797A8 (fr) Compositions assurant le traitement et la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et de glucosamine
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
WO2002080895A3 (fr) Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
WO2001074341A3 (fr) Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 520826

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 018076793

Country of ref document: CN

Ref document number: 2001247867

Country of ref document: AU

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 520826

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520826

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001247867

Country of ref document: AU